Terms: = Breast cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Prognosis
76 results:
1. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Rediti M; Fernandez-Martinez A; Venet D; Rothé F; Hoadley KA; Parker JS; Singh B; Campbell JD; Ballman KV; Hillman DW; Winer EP; El-Abed S; Piccart M; Di Cosimo S; Symmans WF; Krop IE; Salgado R; Loi S; Pusztai L; Perou CM; Carey LA; Sotiriou C
Nat Commun; 2023 Nov; 14(1):7053. PubMed ID: 37923752
[TBL] [Abstract] [Full Text] [Related]
2. Identifying and analyzing the key genes shared by papillary thyroid carcinoma and Hashimoto's thyroiditis using bioinformatics methods.
Liu TT; Yin DT; Wang N; Li N; Dong G; Peng MF
Front Endocrinol (Lausanne); 2023; 14():1140094. PubMed ID: 37324256
[TBL] [Abstract] [Full Text] [Related]
3. Molecular subtypes as a prognostic breast cancer factor in women users of the São Paulo public health system, Brazil.
Peres SV; Arantes PE; Fagundes MA; Ab'Saber AM; Gimenes DL; Curado MP; Vieira RADC
Rev Bras Epidemiol; 2023; 26():e230028. PubMed ID: 37255208
[TBL] [Abstract] [Full Text] [Related]
4. Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins A; Gusterson B; Tovey H; Griffin C; Stuttle C; Daley F; Corbishley CM; Dearnaley D; Hall E; Somaiah N
EBioMedicine; 2023 Feb; 88():104436. PubMed ID: 36708693
[TBL] [Abstract] [Full Text] [Related]
5. Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.
Lin X; Lin X; Guo L; Wang Y; Zhang G
Thorac Cancer; 2022 Dec; 13(24):3441-3450. PubMed ID: 36305094
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic Impact of Radiation Therapy in Pure Mucinous breast Carcinoma.
Chevli N; Wang K; Haque W; Schwartz MR; Nangia J; Sasaki J; Farach AM; Hatch SS; Butler EB; Teh BS
Clin Breast Cancer; 2022 Oct; 22(7):e807-e817. PubMed ID: 35915020
[TBL] [Abstract] [Full Text] [Related]
7. A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National cancer Database analysis.
Cao L; Towe CW; Shenk R; Stabellini N; Amin AL; Montero AJ
Cancer; 2022 Jul; 128(13):2433-2440. PubMed ID: 35363881
[TBL] [Abstract] [Full Text] [Related]
8. B cell-related gene signature and cancer immunotherapy response.
Lundberg A; Li B; Li R
Br J Cancer; 2022 Apr; 126(6):899-906. PubMed ID: 34921229
[TBL] [Abstract] [Full Text] [Related]
9. Local delivery of biocompatible lentinan/chitosan composite for prolonged inhibition of postoperative breast cancer recurrence.
Gu S; Xu J; Teng W; Huang X; Mei H; Chen X; Nie G; Cui Z; Liu X; Zhang Y; Wang K
Int J Biol Macromol; 2022 Jan; 194():233-245. PubMed ID: 34871653
[TBL] [Abstract] [Full Text] [Related]
10. DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer.
Shen N; Korm S; Karantanos T; Li D; Zhang X; Ritou E; Xu H; Lam A; English J; Zong WX; Liu CT; Shirihai O; Feng H
Commun Biol; 2021 Nov; 4(1):1289. PubMed ID: 34785772
[TBL] [Abstract] [Full Text] [Related]
11. Retrospective review of cutaneous metastasis among 11,418 patients with solid malignancy: A tertiary cancer center experience.
Teyateeti P; Ungtrakul T
Medicine (Baltimore); 2021 Jul; 100(29):e26737. PubMed ID: 34398051
[TBL] [Abstract] [Full Text] [Related]
12. Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative breast cancer.
Harris RJ; Cheung A; Ng JCF; Laddach R; Chenoweth AM; Crescioli S; Fittall M; Dominguez-Rodriguez D; Roberts J; Levi D; Liu F; Alberts E; Quist J; Santaolalla A; Pinder SE; Gillett C; Hammar N; Irshad S; Van Hemelrijck M; Dunn-Walters DK; Fraternali F; Spicer JF; Lacy KE; Tsoka S; Grigoriadis A; Tutt ANJ; Karagiannis SN
Cancer Res; 2021 Aug; 81(16):4290-4304. PubMed ID: 34224371
[TBL] [Abstract] [Full Text] [Related]
13. Clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia.
Liu C; Wang C; Du Z; Xue H; Liu Z
Medicine (Baltimore); 2020 Oct; 99(44):e22904. PubMed ID: 33126344
[TBL] [Abstract] [Full Text] [Related]
14. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado cancer Center.
Weiss JA; Nicklawsky A; Kagihara JA; Gao D; Fisher C; Elias A; Borges VF; Kabos P; Davis SL; Leong S; Eckhardt SG; Diamond JR
Cancer Med; 2020 Dec; 9(23):8801-8808. PubMed ID: 33063469
[TBL] [Abstract] [Full Text] [Related]
15. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Sinit RB; Hwang DG; Vishnu P; Peterson JF; Aboulafia DM
BMC Cancer; 2019 Nov; 19(1):1147. PubMed ID: 31775673
[TBL] [Abstract] [Full Text] [Related]
16. Primary hepatic leiomyoma in a Chinese female patient without underlying disease: a case report.
Jia B; Jin Z; Gao P; Liu Y
BMC Surg; 2019 Oct; 19(1):140. PubMed ID: 31590641
[TBL] [Abstract] [Full Text] [Related]
17. Management of biochemical recurrence after radical prostatectomy for prostate cancer: A case report.
Shen J; Zang S; Yu X; Zhao F; Jiang P; Zhong B; Zhou H; Yan S
Medicine (Baltimore); 2019 Jul; 98(27):e16351. PubMed ID: 31277192
[TBL] [Abstract] [Full Text] [Related]
18. cancer survival trends in Kuwait, 2000-2013: A population-based study.
Alawadhi E; Al-Awadi A; Elbasmi A; Coleman MP; Allemani C
Gulf J Oncolog; 2019 Jan; 1(29):39-52. PubMed ID: 30956195
[TBL] [Abstract] [Full Text] [Related]
19. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract] [Full Text] [Related]
20. Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer.
Huang Y; Jiang G; Liang X; Lan Z; Su Z; Wu H; Weng J; Jiang X
Mol Med Rep; 2018 Oct; 18(4):3914-3922. PubMed ID: 30132530
[TBL] [Abstract] [Full Text] [Related]
[Next]
